ILI4 Antibody

What is IL-4 and why are antibodies against it important in research?

IL-4 is a pleiotropic Th2 cytokine (approximately 13-18 kDa) that plays critical roles in immune regulation. It is produced primarily by Th2-biased CD4+ T cells, mast cells, basophils, and eosinophils . IL-4 is synthesized with a 24 aa signal sequence and adopts a bundled four alpha-helix structure with three intrachain disulfide bridges .

IL-4 antibodies are essential research tools for:

• Detecting and quantifying IL-4 in biological samples

• Neutralizing IL-4 activity in functional assays

• Studying the role of IL-4 in various disease models

• Investigating immune cell signaling pathways

Human IL-4 exerts its effects through two receptor complexes:

• Type I receptor (IL-4Rα + common gamma chain) - expressed on hematopoietic cells

• Type II receptor (IL-4Rα + IL-13Rα1) - expressed on non-hematopoietic cells

What are the common applications for IL-4 antibodies in immunological research?

IL-4 antibodies serve multiple crucial functions in immunological research:

For optimal results when detecting IL-4 production in cell cultures, researchers should consider using anti-IL-4R monoclonal antibodies to prevent IL-4 consumption by IL-4R-expressing cells in the culture system, as this can lead to underestimation of IL-4 production .

How do IL-4 antibodies differ in their binding specificities and functional properties?

IL-4 antibodies exhibit different epitope specificities and functional characteristics:

• Epitope Specificity: Different antibodies recognize distinct regions of IL-4 or its receptor. For example, antibody 4R34.1.19 primarily binds to IL-4 binding sites on IL-4Rα with different epitopes from the clinically approved dupilumab analogue .

• Cross-Reactivity: Some antibodies show species-specific binding while others may exhibit cross-reactivity. Human, mouse, and rat IL-4 are generally species-specific in their activities, requiring specific antibodies for each .

• Functional Properties:

  • Neutralizing antibodies: Block IL-4 interaction with its receptor (e.g., MAB304 with ND50 of 0.03-0.1 μg/mL)

  • Detection antibodies: Optimized for specific applications like ELISA or flow cytometry

  • Agonist antibodies: Rare antibodies that can activate signaling (similar to natural ligands)

• Isotype Differences: The antibody isotype (IgG1, IgG2, IgG4, etc.) can influence functionality, half-life, and potential effector functions.

How can I design experiments to evaluate the neutralizing capacity of IL-4 antibodies?

Designing robust neutralization assays for IL-4 antibodies requires careful consideration of several factors:

Methodology:

• Cell-Based Proliferation Assay:

  • Use TF-1 human erythroleukemic cell line which proliferates in response to IL-4

  • Establish dose-response curve with recombinant human IL-4 (typically 0.5 ng/mL)

  • Add increasing concentrations of anti-IL-4 antibody

  • Measure proliferation using appropriate assays (MTT, BrdU, etc.)

  • Calculate ND50 (concentration required for 50% neutralization)

• B Cell Activation Assay:

  • Culture purified human B cells with CD40L-transfected cells and rIL-4

  • B cells become IL-4-responsive through CD40 triggering

  • Add anti-IL-4R antibody at various concentrations

  • Measure B cell proliferation to determine blocking efficiency

• Controls to Include:

  • Positive control: Cells + IL-4 without antibody

  • Negative control: Cells without IL-4 or antibody

  • Isotype control: Irrelevant antibody of same isotype

  • Known neutralizing antibody as reference standard

Data Analysis and Interpretation:

• Plot neutralization percentage against antibody concentration

• Determine ND50 using appropriate curve-fitting software

• Compare results with reference standards (e.g., MAB304 with ND50 of 0.03-0.1 μg/mL)

• Assess specificity by testing against related cytokines (e.g., IL-13)

What strategies can be employed for selecting optimal antibody pairs for IL-4 detection in multiplex assays?

Selecting optimal antibody pairs for IL-4 detection in multiplex assays requires systematic evaluation:

Methodological Approach:

• High-Throughput Screening:

  • Surface plasmon resonance (SPR) measurements

  • Suspension arrays (multiplexed bead arrays)

  • Forward-phase protein microarrays

• Selection Criteria:

  • Non-competitive binding to different epitopes

  • High affinity (typically in the nM or pM range)

  • Specificity (minimal cross-reactivity)

  • Stability in assay conditions

• Validation Process:

  • Test multiple capture and detection antibody combinations

  • Evaluate sensitivity using recombinant standards

  • Assess specificity against related cytokines

  • Confirm performance in complex biological matrices

Example from Research:
A study employing recombinant mouse IL-4 and three different purified rat anti-mouse IL-4 monoclonal antibodies found that SPR measurements and two high-throughput methods (suspension arrays and protein microarrays) consistently identified the same optimal antibody pair: BVD4-1D11 (capture) and BVD6-24G2 (detection). This pair detected as low as 2 pg/mL of IL-4 in buffer solution and 13.5 pg/mL in 100% normal mouse serum with multiplexed bead arrays .

How can advanced computational and machine learning approaches improve antibody discovery for IL-4 targeting?

Modern antibody discovery increasingly leverages computational methods and machine learning:

Advanced Computational Approaches:

• "Lab-in-the-loop" Systems:

  • Integration of generative machine learning models

  • Multi-task property predictors

  • Active learning ranking and selection

  • In vitro experimentation in an iterative optimization loop

• Deep Learning Applications:

  • Prediction of antibody-antigen binding affinities

  • Optimization of complementarity-determining regions (CDRs)

  • De novo antibody design targeting specific IL-4 epitopes

  • Prediction of physicochemical properties

• Practical Implementation:

  • Train models on existing antibody-antigen complex data

  • Generate diverse candidate sequences

  • Rank candidates based on predicted properties

  • Experimentally validate top candidates

  • Feed experimental data back to refine models

Research Outcomes:
Recent work has demonstrated successful application of lab-in-the-loop approaches for therapeutic antibody design, iteratively improving binding affinity by 3-100× through multiple optimization rounds. This approach has been applied to several targets, with the best binders reaching therapeutically relevant 100 pM affinity range .

How can I troubleshoot inconsistent results in IL-4 detection assays?

Inconsistent results in IL-4 detection assays often stem from several factors:

Common Issues and Solutions:

• IL-4 Consumption in Culture:

  • Problem: IL-4R-expressing cells in culture may consume IL-4, leading to underestimation

  • Solution: Add anti-IL-4R antibodies (e.g., clone 25463.11) to block receptor-mediated consumption

  • Evidence: Studies show that adding anti-IL-4R antibody to PBMC cultures stimulated with tetanus toxoid (TT) resulted in detectable IL-4 accumulation that was otherwise undetectable

• Timing of Measurements:

  • Problem: IL-4 production kinetics vary by experimental system

  • Solution: Perform time-course experiments to determine optimal sampling times

  • Evidence: Studies show progressive increase in IL-4 concentrations in supernatants up to day 8 in some culture systems

• Antibody Selection Issues:

  • Problem: Suboptimal antibody pairs may reduce sensitivity

  • Solution: Systematically test different antibody combinations

  • Method: Use suspension arrays or protein microarrays to efficiently evaluate multiple combinations

• Matrix Effects:

  • Problem: Components in biological samples may interfere with detection

  • Solution: Optimize sample dilution, use appropriate blocking reagents, and develop matrix-matched calibration curves

  • Validation: Compare results in buffer vs. biological matrices (e.g., serum)

What techniques can be used to distinguish between IL-4 and IL-13 signaling in complex biological systems?

Distinguishing IL-4 and IL-13 signaling is challenging due to their shared receptor components:

Advanced Methodological Approaches:

• Selective Receptor Blocking:

  • Use antibodies that specifically block IL-4Rα/γc (Type I) versus IL-4Rα/IL-13Rα1 (Type II) interactions

  • Example: Anti-IL-4Rα antibodies like dupilumab block both pathways, while selective IL-13Rα1 antibodies only block Type II signaling

• Genetic Approaches:

  • Use cell lines with selective receptor knockout/knockdown

  • CRISPR-Cas9 modification of specific receptor components

  • Reconstitution experiments with specific receptor chains

• Pharmacological Discrimination:

  • Use cytokine muteins with selective receptor specificity

  • Employ cytokine-antibody complexes with altered receptor selectivity

• Downstream Signaling Analysis:

  • Monitor phosphorylation of STAT6 (common to both pathways)

  • Compare with STAT3 activation (more prominent with IL-13)

  • Analyze gene expression profiles specific to each pathway

  • Use phospho-flow cytometry to analyze signaling in specific cell populations

Example Application:
Studies have identified antibodies that stabilize the ternary complex of IL-4 and its receptor subunits. For instance, researchers found an antibody fragment that stabilizes the IL-4/IL-4Rα/γc complex by interacting at an epitope involving both receptor subunits at the membrane proximal 'stem' interface . This approach allows for selective modulation of Type I receptor signaling.

How can I optimize agonist antibody discovery for IL-4 receptor targets?

Discovering agonist antibodies that activate IL-4 receptor signaling requires specialized approaches:

Optimized Discovery Strategies:

• Function-Based Screening:

  • Autocrine System: Express antibody libraries on the surface of reporter cells

  • Methodology: Clone antibody genes into lentiviral transfer vectors; transduce reporter cells; isolate clones that activate signaling

  • Advantage: Identifies clones with rare biological properties that might be lost during affinity-based screening

• Phage Display + Functional Screening:

  • Combined Approach: Initial enrichment for binders using phage display followed by function-based screening

  • Methodology: Perform one round of phage display to enrich for initial binders, then test in mammalian reporter cells for signal transduction

  • Application: This approach has been successful for other receptors (e.g., APJ receptor) where traditional methods failed to identify agonist antibodies

• Co-culture Systems:

  • Microdroplet Ecosystems: Co-encapsulate antibody-producing cells with reporter cells

  • Example: Co-encapsulating primary B cells (from immunized animals) and reporter cells in agarose-based microdroplets (~100 μm diameter)

  • Innovation: Paracrine-like systems combining phage-producing E. coli with mammalian reporter cells in microdroplet ecosystems

Engineering for Enhanced Agonist Activity:

• Fc Engineering:

  • Introduce mutations (e.g., T437R and K248E) to facilitate hexamerization of antibody Fc regions when bound to receptor

  • This promotes clustering of antibody-bound receptors and enhances signaling

• Isotype Selection:

  • Different IgG subclasses influence agonist activity

  • IgG2 isotype antibodies, particularly the h2B isoform with rearranged hinge disulfide bonds, can adopt more compact conformations that enable closer packing of target receptors

How do IL-4 antibodies differ from IL-4R antibodies in research and therapeutic applications?

IL-4 antibodies and IL-4R antibodies have distinct properties and applications:

Comparative Analysis:

Methodological Insights:

• Anti-IL-4R antibodies like dupilumab block both IL-4 and IL-13 signaling since both cytokines use IL-4Rα

• Engineering approaches have yielded high-affinity anti-IL-4Rα antibodies (e.g., 4R34.1.19 with KD ≈ 178 pM) that effectively block both IL-4- and IL-13-dependent signaling

• Epitope mapping by alanine scanning mutagenesis is crucial to identify antibodies that bind to IL-4 binding sites on IL-4Rα

Functional Validation:
Anti-IL-4Rα antibodies like 4R34.1.19 have been shown to:

• Inhibit IL-4-dependent proliferation of T cells among human PBMCs

• Suppress differentiation of naïve CD4+ T cells from healthy donors and asthmatic patients into TH2 cells

What are the considerations for developing bispecific antibodies targeting IL-4 pathway components?

Developing bispecific antibodies for IL-4 pathway intervention requires careful design considerations:

Strategic Approaches:

• Target Selection Strategies:

  • IL-4 + IL-13: Target both cytokines to block Type 2 inflammation

  • IL-4Rα + IL-13Rα1: Block the Type II receptor complex completely

  • IL-4 + IL-4Rα: Enhanced neutralization through dual targeting

  • IL-4 pathway + complementary pathway (e.g., IL-4 + TSLP or IL-5)

• Format Optimization:

  • Fragment-Based Designs: scFv-Fc, diabody, DART, BiTE

  • IgG-Based Designs: Knobs-into-holes, CrossMAb, DVD-Ig

  • Considerations: Size, half-life, tissue penetration, manufacturing feasibility

• Functional Evaluation:

  • Binding Assessment: SPR/BLI to confirm binding to both targets

  • Cellular Assays: Reporter systems for both pathways

  • Ex vivo Testing: Human PBMC assays, TH2 differentiation

  • In vivo Models: Humanized mouse models of allergic disease

Research Example:
A novel "immunocytokine" has been developed based on sequential fusion of murine IL-4 with the antibody fragment F8 (specific to the alternatively spliced extra-domain A of fibronectin, a marker for tumor-angiogenesis) in diabody format. The F8-IL4 fusion protein retained full antigen-binding activity and cytokine bioactivity, selectively localized to solid tumors in vivo, and showed synergistic effects when co-administered with immunocytokines based on IL-2 and IL-12 .

How can systems serology approaches enhance our understanding of IL-4 antibody functions?

Systems serology provides comprehensive insights into IL-4 antibody functions:

Methodological Framework:

• Multidimensional Profiling:

  • Measure multiple antibody features simultaneously (isotypes, subclasses, glycosylation, Fc receptor binding)

  • Analyze diverse functional activities (neutralization, ADCC, ADCP, CDC)

  • Integrate data using multivariate statistical approaches

• Analysis Techniques:

  • Machine Learning: LASSO feature selection to identify discriminating antibody features

  • Multivariate Statistics: Principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA)

  • Network Analysis: Correlation networks to identify related antibody functions

• Application to IL-4 Research:

  • Compare antibody responses elicited by different adjuvants

  • Identify antibody features that correlate with protection or pathology

  • Characterize the evolution of antibody responses over time

How are antibody engineering techniques advancing the development of next-generation IL-4 targeting therapeutics?

Cutting-edge antibody engineering is revolutionizing IL-4-targeted therapeutics:

Advanced Engineering Approaches:

• Affinity Maturation Techniques:

  • Deep Mutational Scanning: Systematic testing of all possible amino acid substitutions

  • Directed Evolution: Yeast or phage display with stringent selection conditions

  • Computational Design: Structure-based optimization of binding interfaces

  • Outcome: Antibodies with sub-nanomolar affinities (e.g., KD ≈ 178 pM)

• Fc Engineering for Optimal Properties:

  • Half-life Extension: Mutations enhancing FcRn binding (e.g., YTE, LS mutations)

  • Effector Function Modulation: LALA-PG mutations to eliminate ADCC/CDC

  • Stability Enhancement: Disulfide engineering, deamidation-resistant mutations

• Novel Formats for Enhanced Functionality:

  • Bispecific Antibodies: Various formats targeting IL-4 and complementary pathways

  • Antibody-Cytokine Fusions: Direct delivery of immunomodulatory cytokines

  • Multi-specific Antibodies: Targeting multiple components of Type 2 inflammation

Case Study:
Recent research has yielded a first-in-class human IgG4 monoclonal antibody targeting the immunoglobulin-like transcript 4 (ILT4) receptor, MK-4830, which was well-tolerated as monotherapy and in combination with pembrolizumab, with no unexpected toxicities. This antibody demonstrated dose-related evidence of target engagement and antitumor activity, suggesting a potential novel immunotherapy approach that could be combined with IL-4 pathway modulation .

How can we better understand the contradictory roles of IL-4 in different disease contexts through antibody-based studies?

IL-4 has complex, sometimes contradictory roles that can be elucidated through antibody-based research:

Methodological Approaches:

• Context-Specific Neutralization Studies:

  • Use selective neutralizing antibodies in different disease models

  • Compare temporal effects of IL-4 blockade at different disease stages

  • Combine with cell-specific depletion to understand cellular sources and targets

• Dual Reporter Systems:

  • Engineer cells with fluorescent/luminescent reporters for both pro- and anti-inflammatory pathways

  • Use IL-4 antibodies to modulate signaling and observe pathway dynamics

  • Analyze temporal relationship between competing pathways

• Tissue-Specific Delivery:

  • Employ antibody-based targeted delivery of IL-4 to specific tissues

  • Compare effects of local vs. systemic IL-4 neutralization

  • Use bispecific antibodies targeting tissue-specific markers plus IL-4

Research Example:
Studies with F8-IL4 (an immunocytokine based on fusion of murine IL-4 with the antibody fragment F8) showed that despite IL-4's typical association with TH2 responses, it could inhibit tumor growth in immunocompetent murine cancer models. Furthermore, F8-IL4 showed synergistic effects when co-administered with IL-12-based immunocytokines, yielding complete tumor eradication, despite IL-4 and IL-12 typically having opposite immunological mechanisms in T-cell polarization .

What are the challenges and opportunities in developing antibodies that selectively modulate IL-4 signaling through different receptor complexes?

Selectively modulating IL-4 signaling through specific receptor complexes presents unique challenges and opportunities:

Technical Challenges:

• Structural Similarity:

  • Type I (IL-4Rα/γc) and Type II (IL-4Rα/IL-13Rα1) complexes share the IL-4Rα chain

  • Binding epitopes may overlap between receptor configurations

  • Conformational changes upon IL-4 binding affect antibody accessibility

• Cell Type Specificity:

  • Type I receptors predominate on hematopoietic cells

  • Type II receptors are more common on non-hematopoietic cells

  • Tissue penetration differs between antibody formats

• Functional Validation:

  • Limited availability of receptor-specific readouts

  • Need for cell type-specific assay systems

  • Complexity of in vivo models with mixed cell populations

Innovative Solutions:

• Structure-Guided Approaches:

  • Design antibodies targeting the unique interfaces in each receptor complex

  • Develop antibodies that stabilize or destabilize specific receptor conformations

  • Create antibodies that modulate specific receptor-proximal signaling events

• Novel Screening Strategies:

  • Cell-based screens with reporter lines expressing only Type I or Type II receptors

  • High-throughput functional assays measuring distinct downstream signals

  • Phage display selections with recombinant receptor complexes in defined orientations

Successful Example:
Investigators identified a rare antibody that stabilizes the ternary complex of IL-4 (ligand) and IL-4Rα and γc (two receptor subunits). This antibody fragment interacts at an epitope involving both receptor subunits, specifically at the membrane proximal 'stem' interface, and indirectly stabilized ligand binding . Similarly, antibody fragments with interesting specificities were identified, including allosteric, conformationally selective antibodies that bound IFNAR2 (receptor) only upon interferon binding, increasing signaling potency by ~100-fold .